Britain and America have forged a major bilateral deal that will guarantee zero duties on UK pharmaceutical exports going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the NHS. This move secures that import taxes on these vital goods will remain at zero for a period of three years.
This agreement follows previous statements to hike import taxes on patented drug imports, with increases mentioned up to double the cost.
"This deal with the United Kingdom reinforces the international landscape for new treatments and establishes much-needed balance to U.S.–U.K. drug exports," a release noted.
Economic Significance
Medicines are one of the UK's largest exports to the America, which is by far the biggest buyer for leading British pharmaceutical firms.
Statistics show that in the one-year period leading up to September, the UK exported medicines totaling billions to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This guarantee secures jobs, boosts investment and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Key British Pledges
The pact entails several notable changes from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds were more than twenty percent.
Industry Background
The deal follows a ongoing row between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
The disagreement were intensified by assertions that American patients were paying a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS had to increase expenditure on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
